Nathan Slaughter, Chief Investment Strategist of The Daily Paycheck and High-Yield Investing, has developed a long and successful track record over the years by finding profitable investments no matter where they hide. Nathan's previous experience includes a long tenure at AXA/Equitable Advisors, one of the world's largest financial planning firms. He also honed his research skills at Morgan Keegan, where he managed millions in portfolio assets and performed consultative retirement planning services. To reach more investors, Nathan switched gears in 2004 and began writing full-time. He has since published hundreds of articles for a variety of prominent online and print publications. Nathan has interviewed industry insiders like Paul Weisbruch and CEOs like Tom Evans of Bankrate.com, and has been quoted in the Los Angeles Times for his expertise on economic moats. Nathan's educational background includes NASD Series 6, 7, 63, & 65 certifications, as well as a degree in Finance/Investment Management from Sam M. Walton School of Business, where he received a full academic scholarship. When not following the market, Nathan enjoys watching his favorite baseball team, the Cubs, and camping and fishing with his family.
Analyst Articles
In late December 2002, the “dot com” bust was complete and the market was about to close the books on its third straight losing year. Bargains were plentiful and the economy was pulling out of a recession, but investors had had enough and many… Read More
Early March 2009 is not only notable for its cheap stocks. It’s also the strongest the dollar has been since 2006. It’s also the strongest it will be for quite some time. At its high on March 5, it took $1.25 to buy a euro. The dollar has since lost… Read More
On July 18th, Companhia Vale do Rio Doce (NYSE: VALE) said it was not interested in acquiring more fertilizer companies. The statement was made after a Sao Paulo newspaper reported the Brazilian mining company was considering a $25 billion buyout of the Minnesota-based… Read More
Apple (Nasdaq: AAPL) turns in its quarterly report card this evening after the closing bell. Its earnings, like any company’s, are all about the past. With Apple, the direction to look is forward. First, the basics: Apple… Read More
When it rains, it pours. And we’ll see how that bodes for the market as Wall Street is deluged with second-quarter earnings reports today, led by five Dow components during the day and culminating with results from Apple after the… Read More
“In the coming year, the Securities and Exchange Commission will complete its examination of the [nation’s rating agencies] role in rating residential mortgage-backed securities and collateralized debt obligations linked to subprime mortgage loans.” So said… Read More
Everything is relative, especially market valuation. A utility, for instance, with its steady, slow-growth business, is never going to command the earnings multiple of a rapidly growing biotech firm or high-tech upstart. That’s why it’s best to make valuation comparisons within industries. It’s also… Read More
J.P. Morgan Chase & Co. (NYSE: JPM) earned $2.7 billion this quarter, up +36% from $2.0 billion in the second quarter of 2008. Morgan earned 28 cents a share, a -47% decline from 53 cents a share a year ago. The results reflected a charge of $1.1 billion, or 27… Read More
ProShares, a leader in “short” and “ultrashort” shares that profit when baskets of stocks fall in price, has released a new fund with a hybrid strategy of buying certain companies and short-selling others. The fund is the ProShares Credit Suisse 130/30 and trades… Read More
Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More
